Literature DB >> 6045483

Routine high dose excretory urography.

A T Gronner, R S Arkoff, H J Burhenne.   

Abstract

Radiologic evaluation of 316 excretory urograms utilizing a single 50 ml injection of a 50 to 60 per cent tri-iodinated contrast medium indicated that these studies are of better quality than those previously obtained with the injection of 30 ml. The low incidence of side effects coincides with recent reports in the literature that this dosage level is safe. High dose intravenous drip infusion pyelography was necessary only in selected cases. High dose excretory urography is recommended for routine use.

Mesh:

Substances:

Year:  1967        PMID: 6045483      PMCID: PMC1502850     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  7 in total

1.  THE ROUTINE USE OF HIGHER VOLUMES OF CONTRAST MATERIAL TO IMPROVE INTRAVENOUS UROGRAPHY.

Authors:  M J FRIEDENBERG; M R CARLIN
Journal:  Radiology       Date:  1964-09       Impact factor: 11.105

2.  DOUBLE DOSE CONTRAST MEDIUM IN EXCRETORY UROGRAPHY.

Authors:  A D AMAR
Journal:  Surg Gynecol Obstet       Date:  1964-05

3.  HIGH DOSAGE EXCRETORY UROGRAPHY.

Authors:  G ROSS; W J WILSON; V L ROBARDS; I M THOMPSON
Journal:  J Urol       Date:  1964-12       Impact factor: 7.450

4.  IMPROVED DETAIL IN EXCRETORY UROGRAPHY USING TWICE THE AMOUNT OF CONTRAST AGENT.

Authors:  D W MACEWAN
Journal:  J Can Assoc Radiol       Date:  1965-06

5.  Improved excretory urograms by use of second injection of contrast medium.

Authors:  M C WILSON; C L WILSON; E A MENDELSOHN; N E CROW
Journal:  J Urol       Date:  1962-06       Impact factor: 7.450

6.  Intravenous urography in the patient with renal insufficiency.

Authors:  W B SCHWARTZ; A HURWIT; A ETTINGER
Journal:  N Engl J Med       Date:  1963-08-08       Impact factor: 91.245

7.  Intravenous pyelography in children with renal insufficiency.

Authors:  D W MACEWAN; J S DUNBAR; M B NOGRADY
Journal:  Radiology       Date:  1962-06       Impact factor: 11.105

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.